Source briefing
Antimicrobial stewardship in low- and middle-income countries: Access versus adherence
by Kiarah Shchepanik, Anthony D. Bai, Heather Wise Can improving access to antimicrobial guidelines improve prescriber adherence? In a recent study published in PLOS Medicine (the LAMPA trial), a smartphone app did not improve adherence despite enhanced access…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 21, Status: Authorised
Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 21, Status: Authorised
Read →
Source briefing
Communicable disease threats report, 22 – 28 August, week 35
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 22 - 28 August, and includes updates on diphtheria, Ebola, swine influenza A(H1N2), respiratory virus epidemiology, Crimean-Congo haemorrhagic fever, dengue, chikungunya virus disease, Vibrio growth,…
Read →Source briefing
Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 24, Status: Authorised
Read →Source briefing
Enabling equitable open access to commercially funded research publications
by Anja Schmidt, Christopher C. Winchester, Catherine Skobe, Diane R. Stothard, Eric Topol Pharmaceutical companies fund much biomedical research, yet many journals restrict open access publishing options for peer-reviewed articles reporting commercially funded research. Expanded publishing options, such…
Read →Source briefing
A clinical decision support tool for accurate hip fracture prediction: A nationwide cohort study
by Kristian F. Axelsson, Henrik Litsne, Konstantinos Konstantinou, Hussnain Khalid, Aldina Pivodic, Mattias Lorentzon Background Although hip fractures are commonly associated with functional decline, increased morbidity, and mortality, accurate models for both short- and long-term prediction that do…
Read →Source briefing
Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised
Read →Source briefing
Tackling antimicrobial resistance: Information for animal health practitioners
Tackling antimicrobial resistance: Information for animal health practitioners
Read →Source briefing
Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised
Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Bysumlog, insulin lispro, Date of authorisation: 06/05/2026, Revision: 1, Status: Authorised
Read →